We graded 12 mitochondrial-supplement claims — here’s what holds up

Edited by Samael A. Tejada, Founder & Editor-in-Chief

Medically reviewed by Dr. Kendrick Heywood, MD · Medical Director of Liquivida

Medically reviewed by Dr. Christopher Davis, MD · Medical Director of Reveal Vitality

Medically reviewed by Dr. Anil Bajnath, MD · CEO & Founder, Institute for Human Optimization

Medically reviewed by Dr. Asare Christian, MD · Founder & Medical Director, Aether Medicine

Medically reviewed by Dr. Suresh Rajamanickam, MD · Otolaryngologist (ENT)

Medically reviewed by Dr. Eboni Cornish, MD · Associate Medical Director of Amen Clinics

Medically reviewed by Dr. Lana Morrow, Ph.D. · Neuroscientist; Founder & CEO, THINK Interfaces

Walk into any wellness clinic or scroll any longevity feed and you’ll hear the same promises: this precursor “boosts mitochondrial function,” that capsule “creates new mitochondria,” this drip “repairs your cells.” We took the 12 most repeated marketing claims about supplements and mitochondrial health — drawn from product labels, clinic marketing, and social media, not straw men — and graded each one against the human evidence.

The rule was simple: a claim that something “supports mitochondrial health” is only meaningful if it changes something measurable — mitochondrial respiration, ATP output, mitochondrial protein content, mitophagy, or a clinical outcome tied to energy metabolism. Mechanism isn’t evidence. Animal results aren’t human results. And a blood marker isn’t mitochondrial function. Here’s what holds up — and what doesn’t. We revisit and update this report every quarter as new human trials publish.

How we graded the claims

1. Claim inventory: the 12 most-repeated marketing claims about supplements and mitochondrial health, drawn from product labels, clinic marketing, and social media — not straw men.
2. Evidence standard: each claim graded on our five-label system — Established / Preliminary / Extrapolated / Contested / Absent — with one rule: a claim “supports mitochondrial health” is only meaningful if it changes something measurable (mitochondrial respiration, ATP output, mitochondrial protein content, mitophagy, or a clinical outcome tied to energy metabolism).
3. Weighting: human randomized trials with direct mitochondrial endpoints (muscle biopsies, respirometry) weighted above trials with blood biomarkers; animal and cell data flagged as such and never counted as human evidence; company funding disclosed on every industry-sponsored trial.
4. Cutoff: literature reviewed through our 2026 research program, anchored by the NAD+ evidence synthesis (Gallagher et al. 2026 systematic review, 113 studies) and our evidence-graded supplement guide.

The 12 claims, ranked

Ranked from weakest to strongest evidence. Eight of the twelve grade out as Absent — the marketing is doing the work that the human trials never did.

What surprised us most

Most overhyped: the NAD+ category as a whole. Best-funded, best-marketed — and four direct human measurements of mitochondrial function all came back null, while the advertising industry’s self-regulatory body (the National Advertising Division, BBB National Programs) found oral NAD+ has no human clinical evidence of even raising NAD+ levels. Blood-marker marketing is doing all the work.

Most underappreciated: urolithin A. The only claim with a genuine human mitophagy signal from muscle biopsies — with its caveats (missed primary endpoint, company sponsorship) stated plainly. Preliminary beats overhyped.

The meta-finding: across all 12 claims, the pattern holds — deficiency and disease states respond; healthy, replete adults almost never do. The entire category sells deficiency-correction biology at super-dose prices.

The numbers that matter

• “In four human muscle-biopsy trials of nicotinamide riboside, target engagement was confirmed via NAD+ metabolites (whole-blood NAD+ rose only in Elhassan 2019) — but not one found improvement in measured mitochondrial respiration, content, or bioenergetics.” (Dollerup 2020; Remie 2020; Elhassan 2019; Stocks 2021)
• “Oral NR raised whole-blood NAD+ up to 142% within two weeks at 1,000 mg/day (Conze et al. 2019), sustained at ~139% at eight weeks — yet in a 12-week biopsy trial at 2,000 mg/day, muscle NAD+ was unchanged.” (Blood ≠ tissue.)
• “Urolithin A at 500 mg/day was linked to about 12% hamstring-strength gains over four months (≈9.8% at 1,000 mg/day) (Singh et al., Cell Reports Medicine 2022, n=88), with VO₂ peak improved within-group but not vs placebo (p=0.058) — the prespecified primary endpoint missed statistical significance, the manufacturer sponsored the trials, and a separate 12-week trial found no ATP-production or walking benefit vs placebo (Liu et al. 2022).”
• “On October 13, 2025, the advertising industry’s self-regulatory National Advertising Division (BBB National Programs) found there is no human clinical evidence that orally ingested NAD+ — ‘liposomal or otherwise’ — raises NAD+ levels in the body.”
• “A 2026 systematic review of 113 studies (Gallagher et al.) found zero eligible outcomes trials of IV or intramuscular NAD+ for anti-aging or wellness — noting the review’s protocol was not preregistered and its first author is a managing partner of a med spa.”
• “A 2026 multi-cohort analysis (Nature Metabolism) found whole-blood NAD+ remarkably stable across age and lifestyle interventions — challenging blood NAD+ as a biomarker of aging.”
• “Resveratrol’s human data are mixed: 150 mg/day for 30 days improved muscle mitochondrial respiration in obese men (Timmers 2011), while higher doses were null (Poulsen 2013) or blunted training adaptations (Gliemann 2013) — Contested, not disproven.”
• “The longest published NR trials run ~5–6 months (a 24-week long-COVID RCT with 20 weeks at 2,000 mg/day; a 5-month twin study up to 1,000 mg/day) — no safety data exist beyond ~6 months for NR or NMN, and multi-year long-term safety data are absent.”

Key studies cited

• Dollerup et al. 2020; Remie et al. 2020; Elhassan et al. 2019; Stocks et al. 2021 — human muscle-biopsy randomized trials of nicotinamide riboside: target engagement confirmed via NAD+ metabolites (whole-blood NAD+ rose >2-fold only in Elhassan 2019; the others measured muscle or urinary metabolites); mitochondrial respiration, content, and bioenergetics did not improve in any.
• Conze et al. 2019 — oral nicotinamide riboside raised whole-blood NAD+ up to 142% within two weeks at 1,000 mg/day, sustained at ~139% at eight weeks; a separate 12-week biopsy trial at 2,000 mg/day found muscle NAD+ unchanged.
• Singh et al., Cell Reports Medicine 2022 — urolithin A randomized trial (n=88, 4 months): hamstring strength rose ~12% at 500 mg/day and ~9.8% at 1,000 mg/day; increased mitophagy-protein expression; VO₂ peak improved within-group but not vs placebo (p=0.058); prespecified primary endpoint (peak power) missed significance; manufacturer-sponsored.
• Liu et al., JAMA Network Open 2022 — urolithin A randomized trial: no significant improvement in maximal ATP production or six-minute walk performance versus placebo.
• Gallagher et al. 2026 — systematic review of 113 studies: zero eligible outcomes trials of IV or intramuscular NAD+ for anti-aging or wellness. Limitations: protocol not preregistered; first author disclosed as managing partner of a med spa.
• Trętowicz et al., Nature Metabolism 2026 — multi-cohort analysis: whole-blood NAD+ remarkably stable across age and lifestyle interventions, challenging blood NAD+ as a biomarker of aging.
• National Advertising Division (BBB National Programs; industry self-regulation, not a government agency), October 13, 2025 — in a challenge by Niagen Bioscience against Reus Research: no human clinical evidence that orally ingested NAD+, “liposomal or otherwise,” raises NAD+ levels in the body.
• Grant 2019 — IV NAD+ pharmacokinetics: infused NAD+ rapidly cleared and metabolized; no mitochondrial or clinical endpoints established.
• Timmers et al., Cell Metabolism 2011 — 150 mg/day resveratrol for 30 days improved muscle mitochondrial respiration on a fatty-acid substrate in 11 obese men. Poulsen et al., Diabetes 2013 — 1,500 mg/day for four weeks: null metabolic findings in 24 obese men. Gliemann et al., Journal of Physiology 2013 — 250 mg/day attenuated some exercise-training adaptations in older men.
• Yoshino et al., Science 2021 — NMN improved muscle insulin sensitivity in prediabetic postmenopausal women; no rise in muscle NAD+ content; drew a published critique over baseline group imbalance (Brenner, Science 2021).
• Wall et al., Journal of Physiology 2011 — 24 weeks of carnitine plus carbohydrate raised muscle total carnitine ~21%; carbohydrate used to elevate insulin.

Where the evidence stands

• Established: The underlying physiology — magnesium, B vitamins, CoQ10, and carnitine as essential cofactors and components of energy metabolism — is textbook. What is not established is any benefit from super-dosing healthy, replete people.
• Preliminary: Urolithin A has the only genuine human mitophagy signal (one 88-person randomized trial, with caveats). Creatine (deepest human evidence on this end of the list, via phosphocreatine loading) and alpha-lipoic acid have mixed or inconclusive human data — not disproven, not proven.
• Extrapolated: Much of the category’s marketing extrapolates deficiency-correction biology — what helps a deficient or diseased population — to healthy adults. That extrapolation is where the claims break down.
• Contested: Whether whole-blood NAD+ even declines with healthy aging — the core premise of repletion marketing — is now disputed by large-scale human data.
• Absent: Eight of the 12 claims graded Absent, including every mitochondrial-function claim for oral NAD+ precursors in healthy adults: four direct human measurements of mitochondrial function all came back null.